Cargando…
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
The epidermal growth factor receptor (EGFR) is a well-characterized oncogene that is frequently activated by somatic kinase domain mutations in non-small cell lung cancer (NSCLC). EGFR TKIs are effective therapies for NSCLC patients whose tumors harbor an EGFR activating mutation. However, EGFR TKI...
Autores principales: | Lin, Luping, Bivona, Trever G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437267/ https://www.ncbi.nlm.nih.gov/pubmed/22970367 http://dx.doi.org/10.1155/2012/817297 |
Ejemplares similares
-
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Neel, Dana S., et al.
Publicado: (2017) -
AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015) -
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016) -
Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021) -
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
por: Jonsson, Vanessa D., et al.
Publicado: (2017)